AstraZeneca is pleased to see additional data presented at SABCS reinforce that there is no evidence that a sequencing strategy is superior to a 5 year aromatase inhibitor (AIs) strategy. AstraZeneca believes that AIs should be used upfront in all newly diagnosed breast cancer postmenopausal women as it is critical to keep patients cancer free for as long as possible. Complete news at...
Dr. Samir Hanash, Program Head at the Fred Hutchinson Cancer Research Center in Seattle, WA will give the keynote address on the discovery and development of biomarkers at the 2nd annual Oncology Biomarkers Conference on January 19-20, 2009 in Miami, Florida. Dr. Complete news at...
Intercell AG (VSE: ICLL) announced the execution of a contract modification with the U.S. Department of Health and Human Services (HHS). The agreement commits additional funding of USD 12.5 m for Intercell's Pandemic Influenza program. Intercell is developing a Pandemic Influenza Vaccine Patch System that includes an immunostimulant patch administered in conjunction with an injected Pandemic Influenza vaccine (manufactured by Solvay Biologicals, B.V. Complete news at...
In a new tactic in the fight against cancer, Cornell University researcher Michael King has developed what he calls a lethal "lint brush" for the blood -- a tiny, implantable device that captures and kills cancer cells in the bloodstream before they spread through the body. Complete news at...
Vical Incorporated (Nasdaq: VICL) announced that the company's Vaxfectin(R)-formulated H5N1 pandemic influenza DNA vaccines induced T-cell responses against a matching strain of influenza virus and demonstrated cross-clade antibody responses against a different strain in a Phase 1 clinical trial. The company previously reported that the vaccines had achieved potentially protective levels of antibody responses in up to 67% of evaluable subjects in the trial's higher dose cohorts. Complete news at...
Douglas Easton, Ph.D., whose international studies in breast cancer explained the genetic patterns and causes of the BRCA1 and BRCA2 gene mutations which indicate a person's risk for breast cancer, has been selected to receive the inaugural American Association for Cancer Research (AACR) Outstanding Investigator Award in Breast Cancer Research. This award, funded by Susan G. Complete news at...
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment